

1 **Highly multiplexed cytokine analysis of bronchoalveolar lavage and plasma reveals age-** 2 **related dynamics and correlates of inflammation in children.**

3 Shivanthan Shanthikumar^{1,2,3}, Liam Gubbels¹, Karen Davies⁴, Hannah Walker^{1,2,5}, Anson Tsz
4 Chun Wong^{1,2}, Eric Levi^{4,6}, Richard Saffery^{1,2}, Sarath Ranganathan^{1,2,3}, Melanie R.
5 Neeland^{1,2}.

6 ¹ Infection, Immunity and Global Health, Murdoch Children's Research Institute, Parkville,
7 VIC, Australia.

8 ² Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia.

9 ³ Respiratory and Sleep Medicine, Royal Children's Hospital, Parkville, VIC, Australia.

10 ⁴ Otolaryngology, Royal Children's Hospital, Parkville, VIC, Australia.

11 ⁵ Children's Cancer Centre, Royal Children's Hospital, Parkville, VIC, Australia.

12 ⁶ Clinical Sciences, Murdoch Children's Research Institute, Parkville, VIC, Australia.

13 Corresponding author:

14 A/Prof Melanie R. Neeland

15 Murdoch Children's Research Institute, Royal Children's Hospital, VIC, Australia

16 E: melanie.neeland@mcri.edu.au

17

18 **ABSTRACT**

19 Despite the central role of cytokines in mediating inflammation that underlies a range of
20 childhood diseases, cytokine testing remains primarily limited to research settings and
21 surrogate markers of inflammation are often used to inform clinical diagnostic and treatment
22 decisions. There are currently no reference ranges available for cytokines in healthy children,
23 either systemically (in blood) or at sites of disease (such as the lung). In our study, we aimed
24 to develop an openly accessible reference of cytokines in the airways and blood of healthy
25 children spanning 1 to 16 years of age. We examined how cytokine concentration changes
26 during childhood and assessed whether a core set of cytokine markers could be used to
27 indirectly evaluate the response of a broad spectrum of inflammatory analytes. To develop
28 our reference, a total of 78 unique analytes were measured in cell-free bronchoalveolar lavage
29 (BAL) and plasma from 78 children. We showed that age profoundly impacts soluble
30 immune analyte concentration in both sample types and identified a highly correlative core
31 set of 10 analytes in BAL and 11 analytes in plasma capable of indirectly evaluating the
32 response of up to 34 inflammatory mediators. This study addresses an urgent need to develop
33 reference ranges for cytokines in healthy children to aid in diagnosis of disease, to determine
34 eligibility for, and to monitor the effects of, cytokine-targeted monoclonal antibody therapy.

35 **INTRODUCTION**

36 While some established circulating blood markers, such as c-reactive protein (CRP),
 37 erythrocyte sedimentation rate (ESR) and ferritin, are used clinically to assess inflammation
 38 in children, cytokine testing is primarily limited to research settings (1). As a result, clinicians
 39 often use surrogate markers of cytokines to inform diagnostic and treatment decisions. For
 40 example, CRP level is often used as a surrogate of IL-6 and in patients with severe COVID-
 41 19 pneumonia and paediatric multisystem inflammatory syndrome temporarily associated
 42 with SARS-CoV-2 (PIMS-TS), CRP is used to inform treatment with tocilizumab (an anti-IL-
 43 6 monoclonal antibody) (2, 3). Other monoclonal antibodies such as those that target IL-4,
 44 IL-5, IL-13 and thymic stromal lymphopoietin (TSLP) are used for children with severe
 45 asthma, however surrogate markers such as blood eosinophil count or fractional exhaled
 46 nitric oxide are used to determine eligibility for these treatments (4). There is therefore a clear
 47 and urgent need to develop reference ranges for cytokines in healthy children to aid in
 48 diagnosis of disease, to determine eligibility for, and to monitor the effects of,
 49 immunomodulatory treatments (5).

50 The development of reference ranges for systemic cytokines will have wide applicability, as
 51 blood is currently used to assess for inflammation as well as for alterations in immune cell
 52 populations in a range of childhood immune-related conditions (6-8). For diseases that affect
 53 specific organs, reference values that reflect the local tissue are also needed to inform
 54 targeted treatment strategies. For example, respiratory diseases such as asthma and acute
 55 respiratory tract infections are major sources of morbidity and hospitalisation for children
 56 worldwide, yet treatment options are limited and often confer little to no clinical benefit (9).
 57 The development of disease modifying or curative treatment strategies in these children relies
 58 on a better understanding of immunity in the early healthy airway.

59 To address this, we aimed to develop an age-specific and extensive reference of cytokines
 60 and other soluble immune analytes in the airways and blood of children. We also aimed to
 61 investigate how immune analyte concentration changes during childhood and whether a
 62 specific core set of markers could be used to reflect inflammation both locally and
 63 systemically.

64 **RESULTS**

65 **1. Establishing a reference for immune analytes the lower airway and blood of** 66 **children.**

67 We sampled bronchoalveolar lavage (BAL) from 24 children and blood from 66 children
68 undergoing general anaesthesia at the Royal Children's Hospital Melbourne (Figure 1A). The
69 clinical indications for these procedures are provided in Table 1, with 92% (22/24) of the
70 BAL cohort undergoing a procedure for investigation of stridor, and 70% (46/66) of the blood
71 cohort undergoing a procedure for obstructive sleep apnoea (OSA). All children were
72 clinically well at the time of sample collection. Medical history and information on
73 respiratory status from parent questionnaires are also provided in Table 1. All BAL samples
74 were assessed for pathogens as per standard clinical testing in the RCH clinical microbiology
75 laboratory, which included standard culture for bacteria and fungi.

76 Participants were aged between 0.5 and 16 years, and we performed age stratification across
77 infancy (0-2 years), preschool period (3-5 years), childhood (6-10 years), and adolescence
78 (11-16 years). Of the 24 children with BAL samples, 12 had paired blood samples permitting
79 a cross-tissue comparison of analyte levels across the two locations. A total of 78 unique
80 analytes were measured in both the cell-free BAL and blood (plasma) samples using the 48-
81 plex Bio-Plex Pro™ Human Cytokine Screening panel and the 37-plex Bio-Plex Pro™
82 Human Inflammation panel. All data are openly available for reuse in the data repository.

83 **2. Landscape of immune analytes in BAL and plasma.**

84 Of the 78 analytes measured, 32 were detected in both samples, 30 were only detectable in
85 BAL, 3 were only detectable in plasma, and 13 were not detectable in either sample type
86 (Figure 1A, Supplemental Table 1). The cytokines that were undetectable in plasma in our
87 study were also undetectable in another study using the same multiplex panel in plasma of a
88 smaller number of healthy subjects (10). To understand and compare the landscape of soluble
89 immune factors in BAL and plasma, we grouped analytes based on their functional
90 properties.

91 This showed that while the concentrations of analytes differ between the blood and lung, the
92 patterns of relative expression are similar between the two sample types, with CXCL10 and
93 CXCL12 among the most abundant chemokines (Figure 1B), TNFSF13B, sTNF-R1, and
94 sTNF-R2 the most abundant of the TNF superfamily (Figure 1C), sIL-6Ra, sIL-6Rb, and IL-

1Ra the most abundant of the interleukin superfamily (Figure 1D), and inflammatory markers sCD163, SCGF-beta and Osteopontin also highly expressed in both sample types (Figure 1E).

There were 12 children in our cohort with paired BAL and plasma samples, enabling intra-individual analysis of analytes across both tissues (Figure 1F). This revealed that there were 22 analytes significantly more abundant in plasma compared to BAL (all FDR- $p < 0.01$, Figure 1F). There were 3 analytes (IL-1Ra, G-CSF, MIF) significantly more abundant in BAL compared to plasma (all FDR- $p < 0.01$, Figure 1F).

To help develop age-specific references for immune analytes in BAL and plasma, the median and range of each analyte are reported by clinically relevant age groups (infancy, preschool, childhood, adolescence) and presented in Tables 2-3.

3. Immune analyte dynamics over the first 16 years of life.

Principal components analysis (PCA) of BAL analyte data was conducted including age, sex, and BAL pathogen status as demographic variables. This showed that sex and pathogen status did not significantly contribute to variation in our dataset, however age trended towards correlation with the first dimension PC-1 ($R = 0.238$, $p = 0.13$) which explained 36.96% of the variation (Figure 2A). To explore this further, we performed two-tailed spearman correlation analyses of the BAL analyte data which showed 21 analytes were significantly associated with age (raw $p < 0.05$, Figure 2B). The BAL concentration of TNFSF14 and VEGF increased with age, while the concentration of IL-16, FGF2, beta-NGF, IL-4, IL-8, HGF, CXCL1, GCSF, CXCL9, CXCL10, CCL3, IL-2Ralpha, CCL7, CCL27, CCL2, CCL4, SCF, MCSF, and IL-1beta decreased with age. Protein-protein interaction (PPI) and enrichment analysis using STRING revealed that these 21 analytes were highly connected, showing enrichment of pathways associated with chemokine expression and binding, as well as PI3K-Akt signaling (Figure 2C). Of these 21 analytes, only TNFSF14, IL-16 and FGF-2 were significantly associated with age after correction for the false discovery rate (all FDR- $p < 0.05$). Individual dot plots depicting correlations for each of these 21 analytes are presented in Supplementary Figure 1.

PCA of plasma analyte data was also conducted, including age and sex as demographic variables. This showed that sex did not significantly contribute to variation in the plasma dataset, however age was strongly correlated with the first two dimensions PC-1 ($R = 0.32$, $p = 0.00002$) and PC-2 ($R = 0.16$, $p = 0.009$) which together explained 36.6% of the variation (Figure 2D). Two-tailed spearman correlation analyses of the plasma analyte data showed 17

analytes were significantly and negatively correlated with age (raw $p < 0.05$, Figure 2E). PPI and enrichment analysis using STRING revealed that these 17 analytes were highly connected with enrichment of three pathways: chemokine expression and binding, JAK/STAT signaling, and TNFR2 non-canonical NF κ B activation (Figure 2F). Of these 17 analytes, 14 remained significantly associated with age after correction for the false discovery rate (all FDR- $p < 0.05$). These were: TNFRSF8, IL-2R α , GCSF, CXCL9, IFN- γ , IL-18, MCSF, sTNF-R2, CXCL10, IFN- β , CCL11, TNF- β , TNFSF12, CCL4 (Figure 2E). Individual dot plots depicting correlations for all 17 analytes are presented in Supplementary Figure 2.

4. Sex and pathogen status of BAL do not largely modify immune analyte concentration in childhood.

While sex and BAL pathogen status did not appear to contribute to variation by PCA, we wanted to confirm this by directly comparing analyte concentration in males and females for both the BAL and plasma data, as well as pathogen vs no pathogen detected for the BAL data. This revealed that BAL concentrations of IL-9 and IL-10 were slightly higher in males compared to females, and that BAL TNFRSF8 was slightly lower in females compared to males (Supplementary Figure 3A). Plasma concentrations of SCGF- β , TNFSF13B and IFN- β were higher in males compared to females (Supplementary Figure 3B). Of these six analytes, only plasma SCGF- β was significantly different between males and females after correction for the false discovery rate (FDR- $p = 0.005$) (Supplementary Figure 3B). There were no significant differences in BAL analyte concentration in samples with a pathogen detected compared to samples without a pathogen detected. A list of pathogens detected in our cohort is provided in Supplemental Table 2.

5. Discovery of a core set of highly correlated analytes to facilitate clinical application.

While our comprehensive analysis has provided new insights into the soluble immune response in both BAL and plasma of children, not all analytes identified will have clinically accessible tests or a known clinical effect. To address this, we explored the feasibility of identifying a core group of analytes within each tissue that exhibit high correlation. This core set could then be measured in clinical settings to indirectly evaluate the response of other analytes. We also explored whether plasma analyte concentration correlated with BAL analyte concentration in individuals who had both sample types collected, with the goal of

158 identifying markers that could act as proxies for the lung to reduce the need for invasive
159 bronchoscopy for investigation of lung inflammation.

160 Intra-sample correlation analyses revealed robust correlation among analytes in BAL (Figure
161 3A), all with an FDR- $p < 0.001$. Based on these highly correlated analytes, we identified a set
162 of 10 core analytes that could estimate the concentrations of 34 other BAL analytes (Figure
163 3B). The core set of analytes comprises CCL2, Chitinase 3-like 1, FGF2, HGF, IL-17, IL-
164 1alpha, IL-4, IL-5, sTNFR1, and TNFRSF8. Collectively, these analytes exhibit strong
165 correlations with 34 other unique analytes: CCL27, CCL3, CCL4, CCL7, CXCL1, CXCL10,
166 CXCL9, GCSF, IFN-gamma, IL-15, IL-16, IL-18, IL-1beta, IL-1ra, IL-2, IL-2Ralpha, IL-34,
167 IL-6, IL-8, IL-9, LIF, MCSF, Pentraxin-3, sCD163, SCF, sIL-6Ra, sIL-6Rb, sTNFR2, TNF-
168 alpha, TNF-beta, TNFSF10, TNFSF12, TNFSF14, and TNFSF13B.

169 Intra-sample correlation analyses also revealed high correlation among analytes in plasma
170 (Figure 3C), all with an FDR- $p < 0.001$. Based on these highly correlated analytes, we
171 identified a set of 11 core analytes that could estimate the concentrations of 23 other plasma
172 analytes (Figure 3D). The core set of analytes comprises CCL27, CXCL9, IFN-beta, IFN-
173 gamma, IL-16, IL-2Ralpha, IL-32, Osteopontin, sIL-6Rb, sTNFR1, and TNF-beta.
174 Collectively, these analytes exhibit strong correlations with 23 other unique analytes: CCL11,
175 CCL2, CCL4, CCL5, Chitinase 3-like 1, CXCL10, CXCL12, GCSF, HGF, IL-18, IL-1ra, IL-
176 9, MCSF, MIF, MMP2, Osteocalcin, Pentraxin-3, sCD163, SCGF-beta, sIL-6Ra, sTNFR2,
177 TNFRSF8, TNFSF13B.

178 Cross-tissue correlation analyses of paired BAL and plasma samples revealed no significant
179 correlations in analyte levels between the two tissue types in healthy children.

DISCUSSION

We developed an extensive and openly accessible reference of soluble immune analytes in BAL and plasma of healthy children spanning 1 to 16 years of age. We showed that age profoundly impacts soluble immune analyte concentration in both sample types, highlighting the importance of developing age-specific reference datasets for immune responses in the airways and blood of children. We identified a highly correlative core set of 10 analytes in BAL and 11 analytes in plasma that could be measured to indirectly evaluate the response of a broad spectrum of inflammatory analytes, emphasising potential clinical feasibility of this work.

We showed that early life represents an increased state of inflammation compared to later childhood, with a significant number of analytes decreasing throughout childhood in both the airways and circulation. This reflects what has been observed previously in other studies of children and adults, where plasma analytes including CCL4, IL-18, IL-2Ralpha, CXCL9 and IFN-gamma were also shown to reduce with age (10, 11). Immune pathways associated with analytes that changed with age in our plasma data included chemokine receptor binding, JAK-STAT signaling and TNFR2 non-canonical NFκB activation. Increased JAK/STAT signaling is associated with several atopic conditions that are more common in children than adults (12). Furthermore, unregulated JAK/STAT signaling is a potential risk factor for chronic inflammation in the elderly (13). Non-canonical NFκB signaling regulates cell survival, maturation, and proliferation, as well as plays a key role in the development of immune tissues, highlighting the importance of these pathways in early life (14). We also recently showed that proportions of immune cell types associated with JAK/STAT and NFκB signaling, including conventional dendritic cells, monocytes, and B cells, also reduced with age in blood of children (15), providing a potential further link between these pathways and immune development in childhood.

To our knowledge, we are the first to report age-related changes in immune analyte concentration in BAL of healthy children. Like plasma, many analytes reduced with age in BAL, while two (TNFSF14 and VEGF) increased with age. Immune pathways associated with analytes that changed with age in our BAL data include chemokine receptor binding and PI3K-Akt signaling. The PI3K-AKIT signaling pathway has been shown to mediate growth and survival during early lung development in mouse models, and dysregulation of this pathway is associated with the development of lung fibrosis in later life (16-19).

Understanding the normal trajectory of BAL cytokines as children age will allow clinical teams to identify aberrations that occur in different disease states, including the key pathways identified above, and facilitate the use of cytokines as diagnostic biomarkers.

We identified a highly correlative core set of 10 analytes in BAL and 11 analytes in plasma that could be measured to indirectly evaluate the response of a broad spectrum of inflammatory analytes. We developed these core sets of analytes as it is unlikely that all analytes investigated in our study will have a clinically available test and the ability to test a core set of markers as a surrogate for a broad array of immunological features is more clinically feasible. Using such an approach is not implausible, as CRP is currently used as a surrogate for IL-6 concentration, and a high level of CRP is used in clinical decision making around anti-IL6 medication (2, 3). Our core set of 11 plasma analytes allows evaluation of 34 total plasma markers, including IL-18, a key feature of childhood conditions including hemophagocytic lymphohistiocytosis (HLH) and juvenile idiopathic arthritis (20, 21), the TNF and IFN superfamilies which are biomarkers of several autoimmune and inflammatory diseases for which monoclonal antibody therapies are available (22), and osteopontin which has been proposed as a potential biomarker in paediatric cancer patients (23). Our core set of 10 BAL analytes allows evaluation of 44 total BAL markers, including IL-6 which is a key feature of multi system inflammatory syndrome following SARS-CoV-2 infection in children (24), IL-4, Pentraxin-3, and IL-5 which have all been associated with wheezing and asthma in children (25, 26), HGF and FGF2 which are key markers of pulmonary fibrosis seen in paediatric lung diseases of genetic (i.e. disorders of surfactant metabolism) or acquired (i.e. chemotherapy, hypersensitivity pneumonitis, radiation) origin (27, 28), and the chemokine ligand family which are key players in lung diseases that involve inflammatory cell infiltration including paediatric cystic fibrosis (29).

Interestingly, we observed no significant correlation in analyte levels between plasma and BAL in children who had paired samples. This indicates that, in healthy children, systemic cytokine levels may not reflect those in the lung, although we acknowledge the smaller number of participants with matched samples for this analysis. These findings are similar to our previous work that showed no significant correlation in immune cell type proportions between healthy paediatric blood and airway samples (15). While our data suggest that circulating immune markers may not be good proxies for the lung immune response in healthy children, studies investigating respiratory conditions such as asthma, severe COVID-

244 19 and cystic fibrosis have shown that blood markers, including IL-6 and eosinophils,
245 positively correlate with those in BAL during disease (29-31).

246 We acknowledge our samples were collected as part of clinically indicated procedures, which
247 means that not all samples can be considered ‘healthy’. All children were clinically well at
248 the time of sample collection. The main indication in our plasma cohort was OSA, with 70%
249 of samples obtained from children exhibiting or undergoing investigation for this indication.
250 The effect of this underlying condition on our results obtained in plasma is unclear. A recent
251 review revealed conflicting evidence of immune alterations in adult and paediatric OSA, with
252 some studies reporting an inflammatory effect while others reported normal systemic immune
253 responses in these patients (32). The main indication in our BAL cohort was stridor (>90% of
254 the BAL cohort), a sign that affects the upper airway and not the lung and thus should not
255 affect the BAL cytokine profile, and only 1 participant in the BAL cohort had a parent report
256 of ever having asthma. Parent questionnaires revealed that the majority of children in this
257 cohort had never been prescribed respiratory medications (inhaled or oral steroids), and of
258 those prescribed, rates of medication use were similar to what is observed in the Australian
259 community for children aged 0-15years (33). As general anaesthesia is required to collect
260 BAL in children, creating control datasets from healthy children in the community is not
261 feasible. Nevertheless, our cytokine reference can be used as control data for clinical samples
262 collected from children with acute, rare, and chronic respiratory conditions.

263 In this study, we have shown age-related changes in cytokine concentration in both blood and
264 BAL. We identified a core set of cytokines in each tissue that facilitates the clinical
265 translation of our findings. Our work addresses a current knowledge gap regarding age-
266 related trends in systemic and tissue specific cytokine levels that is important to address in
267 the current era of cytokine targeted monoclonal antibody therapy for children in a range of
268 diseases. Our findings will help improve our understanding of the role of inflammation in
269 disease pathogenesis and develop improved biomarkers for disease diagnosis and therapeutic
270 intervention.

MATERIALS AND METHODS

Study participants

This study took place at the Royal Children's Hospital (RCH, Melbourne Australia) and involved analysis of 90 samples (24 BAL, 66 plasma) from 78 children (Table 1) aged between 1 and 16 years. Samples were collected at the time of clinically indicated procedures (bronchoscopy, tonsillectomy and/or adenoidectomy). Reasons for procedures, medical history, and respiratory status of the cohort are documented in Table 1. All children were clinically well at the time of the procedure.

Ethics statement

The studies involving human participants were reviewed and approved by Royal Children's Hospital Human Research Ethics Committee (HREC #25054 and # 88144). Written informed consent to participate in the studies was provided by the participants' legal guardian/next of kin.

Collection and processing of samples

For BAL samples, bronchoscopy and bronchoalveolar lavage were performed as previously described where indicated for investigation of stridor (34). This study used BAL from aliquots two and three from the right middle lobe. BAL was assessed for pathogens as per standard clinical testing in the RCH clinical microbiology laboratory, which included standard culture for bacteria and fungi. Up to 7mL of venous blood was collected in EDTA tubes at the time of the procedure. BAL samples were transferred on ice to the laboratory immediately upon collection. Blood samples were kept at room temperature and processed immediately after collection. BAL samples were centrifuged at 300xg for 7 minutes at 4°C and the cell-free BAL supernatant collected and stored at -80°C. EDTA blood was centrifuged at 700xg for 7 minutes at room temperature and the supernatant (plasma) stored at -80°C.

Analyte quantification using Bio-Plex Pro panels

Cell-free BAL supernatant and plasma samples were thawed, and cytokines were measured using the 48-plex Bio-Plex Pro™ Human Cytokine Screening panel (Bio-Rad, California, USA) and the 37-plex Bio-Plex Pro™ Human Inflammation panel (Bio-Rad, California, USA) according to the manufacturer's instructions. BAL supernatants were run undiluted and plasma samples were diluted 1:5 in phosphate-buffered saline (PBS) as per manufacturers

recommendations. The full list of the 78 analytes measured is provided in Supplementary Table 1. Data were acquired on the Bio-Plex 200 system and data QC was done using the Bio-Plex Manager™ 6.1 software (Bio-Rad). For data QC, standard curve outliers were removed, and individual standards were adjusted to achieve a recovery rate of $100 \pm 5\%$ (observed concentration/expected concentration). A fit probability greater than 0.9 was achieved for each standard curve. The concentration values of each analyte control were then compared to the expected concentration range specified on the assay data sheet for the control lot. Analytes that were not detected in >50% of samples were excluded from further analysis. For each analyte included in the analysis, samples that fell below the detection range were arbitrarily reported as half the lower limit of detection of the assay as previously described for this assay (35). Samples were run over 5 plates for the 48-plex panel, and samples were run over 3 plates for the 37-plex panel. Plate (batch) was included as a variable in the analysis, detailed below.

Data analysis

To identify sources of variation in our data, principal components analysis (PCA) was conducted on log transformed analyte data using the FactoMineR package, including age, sex, plate (batch), and respiratory pathogen status (for BAL data only) as variables. For respiratory pathogen status of BAL samples, this included ‘yes’ or ‘no’ for bacteria and/or fungi detected on culture at the RCH microbiology laboratory (there were no fungi detected in this cohort, see supplement for bacteria detected). As batch contributed significantly to the variation in both the BAL and plasma data (Supplementary Figure 4), we used the ComBat package to adjust for this batch effect. PCA analysis of ComBat-corrected data revealed that batch was effectively adjusted for, and the contribution of other factors including age, sex, and respiratory pathogen status remained unchanged (Supplementary Figure 4). Batch corrected values were used for all analysis presented herein however both uncorrected and batch corrected values are provided in the data repository. For age-specific immune analyte reference ranges (Tables 2-3), the median concentration (pg/mL) was calculated for each immune analyte within each age group (0-2years, 3-5 years, 6-10 years, 11-16 years) and the ranges also reported. There were 12 children in our cohort with paired BAL and plasma samples, enabling intra-individual analysis of analytes across both tissues. Wilcoxon signed-rank tests were used to compare the concentration of analytes between BAL and plasma in children who had both sample types collected (Figure 1F). FDR-corrected p-values are reported and FDR-p<0.05 was considered significant. FDR adjustment was done using the

334 Benjamini and Hochberg approach (36). Age correlations were determined using two-tailed
 335 spearman tests (Figure 4B-E). Both raw ($p < 0.05$) and FDR-corrected ($\text{FDR-}p < 0.05$) p-values
 336 are reported. Analytes that were significantly correlated with age underwent protein-protein
 337 interactions (PPI) and pathway analysis using STRING (version 12) (37) (Figure 4C-F).
 338 Mann-Whitney U-tests were used to compare the concentration of analytes between males
 339 and females (Supplementary Figure 3, raw p-values reported, $p < 0.05$ was considered
 340 significant) and BAL samples with a pathogen vs no pathogen detected (there were no
 341 significant differences). For intra sample type correlations (Figure 3), this was done using
 342 two-tailed spearman tests and FDR-corrected p-values are reported. To ensure the reliability
 343 of our findings, we present only analytes with $\text{FDR-}p < 0.001$ for this analysis, which were
 344 used to generate the ‘core set’ of highly correlative analytes.

REFERENCES

1. S. B. Ali *et al.*, Can C-reactive protein be used as a surrogate marker of IL-6 in a broad array of clinical entities? *Biomark Med* **17**, 1001-1010 (2023).
2. X. Mariette *et al.*, Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. *JAMA Internal Medicine* **181**, 1241-1243 (2021).
3. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet. Child & adolescent health* **8**, 190-200 (2024).
4. G. G. Brusselle, G. H. Koppelman, Biologic Therapies for Severe Asthma. *The New England journal of medicine* **386**, 157-171 (2022).
5. C. Liu *et al.*, Cytokines: From Clinical Significance to Quantification. *Adv Sci (Weinh)* **8**, e2004433 (2021).
6. Y. Ding *et al.*, Reference values for peripheral blood lymphocyte subsets of healthy children in China. *J Allergy Clin Immunol* **142**, 970-973.e978 (2018).
7. E. Blanco *et al.*, Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. *J Allergy Clin Immun* **141**, 2208-2219.e2216 (2018).
8. F. Tosato *et al.*, Lymphocytes subsets reference values in childhood. *Cytometry. Part A : the journal of the International Society for Analytical Cytology* **87**, 81-85 (2015).
9. H. J. Zar, T. W. Ferkol, The global burden of respiratory disease-impact on child health. *Pediatric pulmonology* **49**, 430-434 (2014).
10. G. Kleiner, A. Marcuzzi, V. Zanin, L. Monasta, G. Zauli, Cytokine Levels in the Serum of Healthy Subjects. *Mediators of Inflammation* **2013**, 434010 (2013).
11. L. Sepiashvili *et al.*, Complex biological patterns of soluble cytokines and CD163 in childhood necessitating age-specific reference intervals for evidence-based clinical interpretation. *Clinical biochemistry* **98**, 35-41 (2021).
12. S. Ferreira, E. Guttman-Yassky, T. Torres, Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. *Am J Clin Dermatol* **21**, 783-798 (2020).
13. X. Hu, J. Li, M. Fu, X. Zhao, W. Wang, The JAK/STAT signaling pathway: from bench to clinic. *Signal Transduct Target Ther* **6**, 402 (2021).
14. B. N. Rodriguez, H. Huang, J. J. Chia, A. Hoffmann, The noncanonical NFκB pathway: Regulatory mechanisms in health and disease. *WIREs Mech Dis*, e1646 (2024).
15. S. Shanthikumar *et al.*, A cross-tissue, age-specific flow cytometry reference for immune cells in the airways and blood of children. *medRxiv : the preprint server for health sciences*, 2024.2005.2008.24307019 (2024).
16. J. Wang *et al.*, PI3K-AKT pathway mediates growth and survival signals during development of fetal mouse lung. *Tissue Cell* **37**, 25-35 (2005).
17. D. Khattar *et al.*, PI3K signaling specifies proximal-distal fate by driving a developmental gene regulatory network in SOX9⁺ mouse lung progenitors. *Elife* **11**, e67954 (2022).
18. J. P. Margaria, L. Moretta, J. C. Alves-Filho, E. Hirsch, PI3K Signaling in Mechanisms and Treatments of Pulmonary Fibrosis Following Sepsis and Acute Lung Injury. *Biomedicines* **10**, (2022).
19. J. Wang *et al.*, Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. *Acta Pharm Sin B* **12**, 18-32 (2022).

393 20. M. Mizuta *et al.*, Clinical significance of interleukin-18 for the diagnosis and
394 prediction of disease course in systemic juvenile idiopathic arthritis. *Rheumatology*
395 **60**, 2421-2426 (2020).

396 21. J. M. Krei, H. J. Møller, J. B. Larsen, The role of interleukin-18 in the diagnosis and
397 monitoring of hemophagocytic lymphohistiocytosis/macrophage activation
398 syndrome - a systematic review. *Clin Exp Immunol* **203**, 174-182 (2021).

399 22. M. Croft *et al.*, TNF superfamily in inflammatory disease: translating basic insights.
400 *Trends Immunol* **33**, 144-152 (2012).

401 23. G. Karpinsky *et al.*, Osteopontin: its potential role in cancer of children and young
402 adults. *Biomark Med* **11**, 389-402 (2017).

403 24. N. A. Nakra, D. A. Blumberg, A. Herrera-Guerra, S. Lakshminrusimha, Multi-System
404 Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection:
405 Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed
406 Management. *Children* **7**, 69 (2020).

407 25. H. H. De Keyser, B. Chipps, C. Dinakar, Biologics for Asthma and Allergic Skin
408 Diseases in Children. *Pediatrics* **148**, (2021).

409 26. M. R. Neeland *et al.*, Pulmonary immune profiling reveals common inflammatory
410 endotypes of childhood wheeze and suppurative lung disease. *Mucosal Immunol*,
411 (2024).

412 27. A. P. Laddha, Y. A. Kulkarni, VEGF and FGF-2: Promising targets for the treatment
413 of respiratory disorders. *Respir Med* **156**, 33-46 (2019).

414 28. E. M. DeBoer *et al.*, Imaging of pulmonary fibrosis in children: A review, with
415 proposed diagnostic criteria. *Pediatric pulmonology* **59**, 845-854 (2024).

416 29. S. Shanthikumar, S. C. Ranganathan, R. Saffery, M. R. Neeland, Mapping Pulmonary
417 and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis.
418 *Frontiers in immunology* **12**, 733217 (2021).

419 30. R. Saji *et al.*, Combining IL-6 and SARS-CoV-2 RNAemia-based risk stratification
420 for fatal outcomes of COVID-19. *PLoS One* **16**, e0256022 (2021).

421 31. T. Guiddir *et al.*, Neutrophilic Steroid-Refractory Recurrent Wheeze and Eosinophilic
422 Steroid-Refractory Asthma in Children. *The journal of allergy and clinical*
423 *immunology. In practice* **5**, 1351-1361.e1352 (2017).

424 32. K. Ludwig, T. Huppertz, M. Radsak, H. Gouveris, Cellular Immune Dysfunction in
425 Obstructive Sleep Apnea. *Front Surg* **9**, 890377 (2022).

426 33. A. I. o. H. a. Welfare, Asthma. (2023).

427 34. P. D. Sly *et al.*, Risk factors for bronchiectasis in children with cystic fibrosis. *N Engl*
428 *J Med* **368**, 1963-1970 (2013).

429 35. N. L. Messina *et al.*, Off-target effects of bacillus Calmette-Guérin vaccination on
430 immune responses to SARS-CoV-2: implications for protection against severe
431 COVID-19. *Clin Transl Immunology* **11**, e1387 (2022).

432 36. Y. Benjamini, Y. Hochberg, Controlling the False Discovery Rate - a Practical and
433 Powerful Approach to Multiple Testing. *J R Stat Soc B* **57**, 289-300 (1995).

434 37. D. Szklarczyk *et al.*, STRING v11: protein-protein association networks with
435 increased coverage, supporting functional discovery in genome-wide experimental
436 datasets. *Nucleic acids research* **47**, D607-d613 (2019).

437

438

439 **CONFLICT OF INTEREST**

440 The authors declare no conflicts of interest.

441 **ACKNOWLEDGEMENTS**

442 This work was funded by Chan Zuckerberg Initiative Single-Cell Biology Grants (2021-
443 237883, 2020-217531). We thank the children and parents who participated in our studies,
444 without whom this work would not exist.

445 **Table 1.** Demographics and clinical characteristics of the study cohort.

	BAL cohort	Plasma cohort
Total number	24	66
Age: years, median (range)	3.31 (0.48-12.36)	6.3 (0.48-16.27)
Sex: male, n (%)	19 (79.2)	40 (60.6)
Reason for procedure, n (%)		
-OSA	1 (4.2)	46 (69.7)
-stridor	22 (91.6)	10 (15.15)
-other (hearing concerns, nasal obstruction, tonsillitis)	1 (4.2)	10 (15.15)
Familial atopy, n (%)	7 (29.2)	37 (56.1)
Personal atopy, n (%)	4 (16.2)	25 (37.8)
Parent report of doctor- diagnosed asthma, n (%)	1 (4.2)	18 (27.2)
Any smoke exposure, n (%)	3 (12.5)	16 (24.2)
Antibiotic use past 12 months, n (%)	9 (37.5)	22 (33.3)
Inhaled steroid use past 12 months, n (%)	7 (29.2)	8 (12.1)
Oral steroid use past 12 months, n (%)	7 (29.2)	14 (21.2)

446

447

448 **Table 2.** Immune analyte concentration in BAL cell-free fluid from children aged 0-12 years.

449

Analyte pg/mL [median, (range)]	Infant (0-2years, n=9)	Preschool (3-5 years, n=7)	Childhood (6-12 years, n=8)
beta-NGF	2.28 (0.14-4.57)	0.49 (0.14-2.48)	0.28 (0.14-1.68)
CCL11	1.57 (0.51-5.62)	1.60 (0.75-13.18)	1.37 (0.45-4.79)
CCL2	11.61(3.57-39.58)	9.06 (2.12-13.55)	5.71 (1.07-29.18)
CCL27	7.85 (2.97-14.65)	5.47 (0.51-8.50)	4.81(3.13-12.49)
CCL3	1.56 (0.52-28.47)	0.72 (0.10-4.77)	0.64 (0.05-2.63)
CCL4	15.26 (2.04-133.97)	7.84 (2.12-52.03)	4.68 (0.58-22.74)
CCL7	1.72 (0.16-4.50)	1.15(0.24-1.67)	0.84 (0.38-2.24)
Chitinase 3-like 1	8767.81 (954.10-11894.44)	2864.00 (703.30-8587.37)	3385.45 (839.46-14951.47)
CXCL1	1493.99 (237.68-3093.06)	303.11 (60.76-1122.80)	234.58 (96.67-7357.27)
CXCL10	183.82 (6.50-40684.16)	61.06 (11.02-362.29)	23.78 (8.68-572.92)
CXCL12	8.07 (3.57-18.02)	12.66 (6.60-22.12)	9.45 (1.79-25.59)
CXCL9	102.39 (9.60-2293.80)	55.80 (8.08-248.97)	14.78 (0.40-142.37)
FGF2	6.23 (1.41-18.51)	1.50 (0.03-3.89)	1.14 (0.03-5.24)
G-CSF	474.44 (48.84-2019.92)	151.18 (61.40-1144.81)	92.42 (25.30-369.67)
gp130/sIL-6Rb	5403.32 (1858.12-14458.50)	5711.40 (2976.97-11110.45)	4328.44 (1369.89-21613.27)
HGF	30.89 (3.22-98.99)	26.29 (5.13-159.49)	11.02 (5.13-29.43)
IFN gamma	8.69 (1.05-26.90)	4.48 (0.08-17.63)	5.29 (0.08-12.96)
IL-1 alpha	7.31 (2.35-27.47)	5.33 (0.39-45.19)	3.89 (2.39-12.01)
IL-1 beta	7.27 (0.03-47.24)	0.90 (0.03-9.20)	0.46 (0.03-8.89)
IL-10	2.08 (0.40-5.41)	2.17 (0.40-4.24)	1.94 (0.95-3.35)
IL-12 (p40)	18.35 (2.84-33.53)	9.13 (2.84-25.08)	8.05 (2.84-29.40)
IL-13	0.85 (0.39-2.06)	0.64 (0.36-1.15)	0.82 (0.30-1.34)
IL-15	84.58 (8.71-194.31)	77.20 (51.35-132.44)	98.45 (34.35-173.07)
IL-16	71.13 (45.09-519.98)	29.91 (11.98-184.16)	14.85 (5.32-177.58)
IL-17	2.71 (1.65-4.08)	2.32 (0.78-7.75)	1.56 (0.38-5.06)
IL-18	9.16 (4.37-35.41)	7.31 (0.62-21.76)	5.58 (1.53-25.90)
IL-1ra	841.48 (305.87-3460.55)	503.83 (253.67-1973.83)	531.47 (199.02-2576.00)
IL-2	1.62 (1.29-3.73)	1.62 (0.68-2.79)	1.13 (0.35-6.59)
IL-2Ralpha	3.34 (0.22-7.32)	1.82 (0.55-4.60)	2.04 (0.55-4.35)
IL-3	0.31 (0.01-1.69)	0.03 (0.01-0.78)	0.04 (0.01-0.51)
IL-32	26.61 (2.91-37.78)	24.66 (13.08-63.10)	31.60 (16.33-64.43)
IL-34	6.77 (6.06-25.49)	16.71 (6.06-35.06)	12.09 (6.06-70.04)
IL-4	0.82 (0.10-2.08)	0.47 (0.05-1.46)	0.34 (0.05-1.03)
IL-5	32.45(5.50-235.57)	22.78 (11.47-232.32)	69.31 (5.50-232.32)

IL-6	3.07 (1.29-74.55)	1.29 (0.51-11.76)	2.16 (1.29-5.55)
IL-7	18.13 (9.13-34.54)	25.46 (10.41-76.64)	14.03 (4.56-28.44)
IL-8	206.62 (16.36-1979.35)	28.71 (11.40-466.63)	18.39 (1.66-508.75)
IL-9	3.93 (2.92-18.31)	6.43 (0.98-10.17)	4.52 (0.98-8.79)
LIF	8.45 (3.08-24.23)	9.72 (4.17-23.77)	8.69 (4.55-27.80)
M-CSF	5.94 (2.39-14.02)	4.14 (2.22-6.59)	2.91 (0.88-10.55)
MIF	2309.53 (671.98-4427.52)	1407.09 (582.55-2632.62)	1557.91 (458.98-3935.37)
MMP3	130.69 (25.81-719.08)	130.69 (130.69-1370.04)	110.66 (25.81-207.94)
Osteocalcin	12.66 (12.66-61.51)	43.19 (13.97-190.37)	12.66 (4.81-161.20)
Osteopontin	591.14 (143.74-1061.32)	425.09 (143.74-775.14)	681.92 (557.04-877.56)
PDGF-BB	27.12 (3.50-46.90)	11.29 (1.80-43.16)	14.32 (3.56-52.21)
Pentraxin-3	251.90 (49.75-2144.92)	215.50 (31.71-3812.99)	131.30 (12.44-779.66)
sCD163	16062.05 (2655.74-26156.78)	6774.56 (3050.64-13078.39)	9152.16 (2594.73-39100.43)
SCF	11.75 (7.29-41.50)	9.62 (4.39-24.44)	8.12 (3.86-24.00)
SCGF-beta	1002.49 (59.20-2993.31)	1234.21 (511.18-2660.58)	833.74 (29.60-1649.17)
sIL-6Ra	196.55 (47.65-434.82)	194.61 (27.94-420.01)	181.16 (20.03-577.74)
sTNF-R1	214.24 (75.85-301.29)	200.16 (62.47-397.03)	172.97 (78.42-405.91)
sTNF-R2	33.53 (11.31-46.82)	28.42 (21.93-58.37)	29.22 (20.38-46.82)
TNF-alpha	14.41 (4.67-32.43)	12.04 (4.47-34.44)	10.61 (4.47-20.24)
TNF-beta	2.74 (0.22-11.26)	3.42 (0.22-8.80)	1.76 (0.22-4.60)
TNFRSF8	3.62 (1.36-14.01)	4.46 (1.36-21.95)	4.49 (1.36-11.90)
TNFSF10	30.41 (6.43-264.37)	25.00 (1.81-61.10)	14.16 (3.29-71.33)
TNFSF12	24.80 (6.57-33.94)	17.42 (12.00-46.36)	22.80 (8.80-124.91)
TNFSF13	40392.59 (23946.35-226916.66)	20846.51 (5411.46-77494.32)	34998.56 (4174.88-119099.10)
TNFSF13B	1027.60 (99.88-4744.95)	827.25 (462.14-4396.61)	654.38 (236.40-2213.60)
TNFSF14	0.31 (0.31-7.16)	5.43 (0.31-7.16)	7.16 (0.61-12.30)
TSLP	0.20 (0.10-10.34)	1.66 (0.10-7.31)	1.51 (0.10-8.11)
VEGF	12.13 (1.73-167.73)	82.71 (1.73-209.38)	56.49 (25.99-205.07)

450

451

452 **Table 3.** Immune analyte concentration in plasma from children aged 0-16 years.

Analyte pg/mL [median, (range)]	Infant (0-2years, n=10)	Preschool (3-5 years, n=21)	Childhood (6-10 years, n=22)	Adolescence (11-16 years, n=13)
CCL11	23.18 (9.58-84.99)	19.38 (1.10-45.87)	13.15 (5.50-57.09)	9.98 (1.10-36.13)
CCL2	23.49 (5.58-44.37)	17.15 (3.39-51.76)	15.99 (1.74-30.91)	13.66 (1.74-30.91)
CCL27	198.40 (117.10-293.63)	173.03 (100.03-399.09)	162.13 (104.22-331.70)	145.79 (72.49-320.53)
CCL4	172.80 (119.46-214.33)	192.20 (97.87-234.36)	153.79 (112.18-263.28)	144.31 (101.71-201.84)
CCL5	4177.71 (2713.73-8015.05)	4202.67 (1033.84-8204.98)	3983.05 (2143.14-7582.60)	2829.16 (1048.29-6880.26)
Chitinase 3-like 1	2596.10 (1552.31-7024.70)	2516.86 (733.91-3752.57)	2373.99 (1384.95-4157.89)	2742.96 (619.10-8551.33)
CXCL10	212.05 (96.42-543.98)	228.10 (26.77-820.49)	122.72 (47.46-380.63)	77.61 (47.46-294.65)
CXCL12	408.73 (160.90-820.30)	451.94 (195.36-1200.98)	421.68 (233.94-613.11)	398.93 (257.78-749.61)
CXCL9	430.80 (93.85-1071.94)	269.87 (50.77-2985.30)	155.22 (58.26-678.40)	88.07 (41.55-219.88)
G-CSF	116.57 (24.76-152.22)	103.97 (16.80-461.44)	54.95 (16.80-229.13)	44.63 (16.80-103.97)
gp130/sIL-6Rb	43169.60 (31111.97-66378.76)	42195.48 (16316.25-57797.16)	42237.24 (26541.97-88045.70)	42245.00 (27559.36-98784.15)
HGF	212.31 (160.90-484.38)	191.34 (77.71-393.44)	182.28 (116.16-498.00)	209.38 (97.01-302.33)
IFN-b	27.89 (17.93-47.31)	23.09 (2.38-40.77)	18.21 (11.02-44.00)	20.47 (6.14-28.63)
IFN-y	19.96 (4.86-107.49)	15.45 (2.43-83.70)	12.02 (2.43-39.02)	4.86 (2.43-19.46)
IL-16	42.84 (31.28-110.58)	61.34 (21.87-293.72)	69.82 (15.40-319.00)	58.40 (24.99-161.52)
IL-18	61.82 (24.97-153.02)	45.29 (7.76-215.64)	26.99 (0.83-84.66)	27.53 (9.58-56.16)
IL-1ra	286.16 (173.27-543.33)	294.71 (149.56-556.97)	328.53 (119.09-503.00)	303.63 (50.45-520.95)
IL-2Ralpha	109.62 (85.51-336.83)	94.91 (40.24-192.19)	68.78 (25.12-126.38)	49.05 (17.79-95.79)
IL-32	87.05 (35.12-141.98)	60.58 (17.77-129.91)	64.98 (12.41-117.79)	56.28 (5.31-100.00)
IL-9	445.69 (327.58-578.53)	480.18 (241.67-561.13)	385.53 (259.31-698.90)	388.27 (288.37-624.03)
M-CSF	13.90 (7.50-35.84)	10.57 (1.60-36.80)	7.62 (1.60-23.62)	6.90 (1.60-16.63)
MIF	726.01 (428.10-1290.45)	939.32 (205.67-1809.94)	876.66 (385.50-2257.42)	1049.03 (207.09-1700.9)
MMP2	17340.48 (8729.47-36734.68)	16119.55 (6708.58-27039.07)	12801.61 (5844.31-34301.90)	16114.69 (1750.16-34558.64)
Osteocalcin	4043.32 (2792.44-5887.91)	3970.84 (1702.10-8338.08)	4057.51 (1304.42-7272.78)	4106.13 (1332.68-8915.56)
Osteopontin	47020.08 (33621.91-99030.07)	41887.55 (16300.23-70515.61)	44788.74 (24948.42-81080.82)	46935.05 (20099.78-111027.38)
Pentraxin-3	12686.39 (6965.05-26118.35)	9822.07 (1796.25-23211.50)	11127.18 (4714.23-27852.32)	8256.14 (1383.34-31842.04)
sCD163	56866.33 (32788.18-183229.97)	43004.83 (12842.22-142352.08)	37352.46 (19757.93-102636.90)	41664.56 (17482.61-93158.19)
SCGF-beta	38390.39 (28917.70-57447.48)	35604.97 (16248.82-47686.49)	28505.78 (13325.99-46096.23)	32903.42 (12856.50-54756.44)
sIL-6Ra	6605.90 (5614.23-15726.64)	7915.80 (1820.17-14690.32)	6852.21 (3829.03-12435.15)	8314.40 (3028.12-10335.88)
sTNF-R1	448.58 (250.07-897.30)	264.12 (116.94-562.76)	289.89 (133.21-612.06)	267.18 (43.34-771.93)
sTNF-R2	299.79 (243.75-461.46)	262.02 (108.98-368.96)	231.30 (179.17-357.47)	237.42 (139.83-370.86)
TNF-beta	312.84 (211.90-385.36)	291.32 (172.50-406.08)	255.43 (164.04-456.77)	231.05 (166.32-327.68)
TNFRSF8	2982.19 (1900.97-8806.88)	2800.79 (505.38-7161.09)	1727.14 (681.48-2687.69)	1019.36 (449.76-1790.75)
TNFSF12	184.89 (79.94-271.97)	166.51 (70.70-241.90)	169.01 (103.07-274.80)	144.77 (56.60-323.16)
TNFSF13B	5291.65 (3620.37-9854.53)	4879.07 (1975.04-7382.17)	5058.65 (2458.21-9941.11)	4794.56 (3013.45-11110.11)

453


FIGURE LEGENDS

Figure 1. Landscape of soluble immune analytes in bronchoalveolar lavage (BAL) and plasma of healthy children. (A) Overview of the experimental design and a venn diagram depicting the overlap in the number of analytes detected in BAL vs plasma. Median concentration (pg/mL) of (B) chemokine family analytes, (C) interferon / TNF superfamily analytes, (D) interleukin superfamily analytes and (E) growth factors in BAL (n=24) and plasma (n=66). (F) Ballon plot depicting intra-individual comparison of analyte concentration between BAL and plasma for the 32 analytes detected across both samples in children who had both sample types collected (n=12). *Depicts significant difference by Wilcoxon signed-rank test and correction for the false discovery rate using the Benjamini Hochberg approach (FDR-p<0.05 was considered significant).

Figure 2. Immune analyte dynamics over the first 16 years of life. (A) Principal components analysis (PCA) of BAL immune analyte data highlighting age as a significant contributor to the first dimension. (B) Spearman coefficient and p-values for BAL analytes that were significantly associated with age. *Indicates analytes that were significant after correction for the false discovery rate (FDR). (C) Protein-Protein Interaction (PPI) analysis using STRING reveals significant interactions between BAL analytes associated with age (the strength of the line indicates the confidence of the interaction) and shows enrichment of pathways associated with chemokine receptor binding and PI3K-Akt signaling. (D) PCA of plasma immune analyte data highlighting age as a significant contributor to the first dimension. (E) Spearman coefficient and p-values for plasma analytes that were significantly associated with age. *Indicates analytes that were significant after FDR correction. (F) PPI analysis using STRING reveals significant interactions between plasma analytes associated with age and shows enrichment of pathways associated with chemokine receptor binding, JAK/STAT signaling and TNFR2 non-canonical NFκB activation. Correlation p-values were determined by two-tailed spearman test and p<0.05 was considered significant.







Figure 3. Discovery of a core set of highly correlated analytes. (A) Spearman correlation analyses of analytes within BAL. The red circles indicate a significant correlation after correction for the false discovery rate (all FDR-p<0.001). The strength of the colour indicates the strength of the correlation (spearman rho). (B) Chord plot depicting the BAL analytes with the highest number of correlations. This core set of analytes (right hand side) strongly correlate with 34 other unique analytes (left hand side). (C) Spearman correlation analyses of

486 analytes within plasma. The red circles indicate a significant correlation after correction for
 487 the false discovery rate (all FDR- $p < 0.001$). The strength of the colour indicates the strength
 488 of the correlation (spearman rho). **(D)** Chord plot depicting the plasma analytes with the
 489 highest number of correlations. This core set of analytes (right hand side) strongly correlate
 490 with 23 other unique analytes (left hand side).

A**78 children: 90 samples**


BAL cell-free fluid
Plasma

**Multiplex
immunoassays:**
78 immune analytes


**B****Chemokines****BAL****PLASMA****C****Interferon / TNF superfamily****BAL****PLASMA****D****Interleukin superfamily****BAL****PLASMA****E****Growth factors / other analytes****BAL****PLASMA****F**

A


BAL



B




C




- Chemokine receptors bind chemokines
- PI3K-Akt signaling

D


PLASMA



E



F



- Chemokine receptors bind chemokines
- JAK-STAT signaling
- TNFR2 non-canonical NF κ B pathway

